PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-95.21%
Negative revenue growth signals a shrinking top line, alarming for Benjamin Graham. Confirm if it’s cyclical or structural before proceeding.
-116.81%
Negative gross profit growth suggests either falling sales or rising direct costs. Benjamin Graham would consider this a fundamental warning sign.
-52.01%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
-52.01%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
-52.47%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
-43.48%
Negative EPS growth underscores deteriorating earnings per share. Benjamin Graham would worry about ongoing dilution or weakened profitability.
-43.48%
Negative diluted EPS growth suggests diluted shares grew or net income fell. Benjamin Graham would see this as a serious setback to shareholder value.
7.17%
Share count growth exceeding +3% – Notable dilution. Philip Fisher would want justification for new share issuance or acquisitions.
7.17%
Diluted share count growth above 3% – Noticeable dilution. Philip Fisher would question the rationale for issuing more stock or options.
No Data
No Data available this quarter, please select a different quarter.
582.93%
OCF growth above 20% – Exceptional cash generation improvement. Warren Buffett might see if the net margin also rises in tandem.
577.68%
FCF growth above 20% – Very attractive to value investors. Warren Buffett would check if capital expenditures remain sensible to maintain this level.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9508.05%
10Y OCF/share CAGR above 15% – Outstanding long-term cash-generation growth. Warren Buffett would check if reinvestment needs remain manageable.
131.96%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
210.81%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
88.12%
10Y net income/share CAGR above 15% – Exceptional long-term profit growth. Benjamin Graham would confirm if these gains hold through economic cycles.
91.00%
5Y net income/share CAGR above 15% – Strong mid-term profit growth. Benjamin Graham would check if leverage artificially boosts earnings.
67.11%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
1963.85%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
-27.97%
Negative 5Y equity/share CAGR suggests net worth destruction. Benjamin Graham would see if failing profitability or large payouts cause it.
5.99%
3Y equity/share CAGR 5-8% – Solid. Seth Klarman might see a healthy short-term ROE fueling book value growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.35%
Asset growth above 20% – Rapid expansion. Warren Buffett checks if returns justify this investment and if debt finances it unsafely.
5.97%
5-8% annual BV/share growth – Decent. Seth Klarman monitors if ROE supports continued expansions.
1244.16%
Debt growing over 10% yoy – Potentially high risk. Philip Fisher demands a clear rationale and profitable expansions to offset the debt load.
6.71%
R&D growth 0-10% – Balanced approach. Seth Klarman sees manageable cost if new products are still in development.
86.34%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.